GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698 
Open to Enrollment: Yes 

GOG 0274: The OUTBACK Trial: A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Aims: The purpose of this study is to compare standard treatment; radiation therapy combined with the chemotherapy drug cisplatin (called chemo-radiation), to standard treatment plus additional investigational chemotherapy with the FDA approved agents, carboplatin and paclitaxel. The study will see if the addition of these chemotherapy agents will reduces the risk of tumor recurrence and improves overall survival. 
Diagnosis: Advanced Cervical Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-455
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

Randomized Controlled Pilot Trial of Vitamin D3 Replacement or Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
Aims: Ovarian cancer is the leading cause of death among women with gynecologic cancer. Women with a genetic mutation and a family history of breast and ovarian cancer are at high risk of developing ovarian, fallopian, and primary peritoneal cancer. Novel treatments other than surgery which can decrease the risk of developing ovarian, fallopian tube, and primary peritoneal cancer are important. Some research studies have shown that Vitamin D may reduce the risk of some cancers, including ovarian cancer. This study will examine if high dose Vitamin D is tolerable, and see what effects it may have on cells in the ovary related to the biology of cancer, including how cell growth and cell death is regulated. Information gained from this study may help direct future research studies.
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-222
Sponsor: Northwestern University Department of Obstetrics and Gynecology
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0277: A Phase III Randomized Trial of Gemcitabine (NSC #613327) plus Docetaxel (NSC #628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Aims: In this study, we are looking to see if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was found only in the uterus, decreases the chance that the leiomyosarcoma will come back (recur).
Diagnosis: Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-299
Sponsor: Gynecologic Oncology Group (GOG)  
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

 

× Alternate Text